Necropsy brain tissue from normal (control) patients and patients with depression and dementia was examined for activities of various cholinergic components, and these related to the degree of senile plaque formation and extent of intellectual impairment. Choline acetyltransferase and acetylcholinesterase activities decreased significantly as the mean plaque count rose, and in depressed and demented subjects the reduction in choline acetyltransferase activity correlated with the extent of intellectual impairment as measured by a memory information test; muscarinic cholinergic receptor binding activity remained unchanged with increasing senile plaque formation but butyrylcholinesterase activity increased.
Introduction
The clinical and neuropathological features of senile dementia of Alzheimer type (SDAT) are well established but neurochemical observations are few. Consistent reports of a cholinergic abnormality have been published.1-3 Enzymes that synthetise and degrade acetylcholine-namely, choline acetyltransferase (CAT)'-3 and acetylcholinesterase (ACE)' 4-are significantly decreased in SDAT compared with normal brain tissue. The reduction in CAT activity in certain brain regions tends to parallel the distribution of histopathological abnormalities, which may indicate an association with the disease itself rather than with non-specific factors such as cerebral malfunction, drug treatment, and terminal disease.
We have investigated the quantitative relation between the numbers of senile plaques (one of the most prominent pathological changes in SDAT) and cholinergic biochemical activities. Since senile plaques occur in normal old age and their numbers correlate significantly with the degree of cognitive impairment,6 measuremcnt of cholinergic activities in brain samples with varying degrees of senile change may elucidate further the relation between changes in the cholinergic system and a major aspect of the Alzheimer disease process.
Materials and methods
Clinical-All subjects examined were hospital patients aged 61-92 years from an acute medical unit or a psychogeriatric department; 13 were normal (these served as controls), 10 (5) Dementia of "mixed" pathology-These patients were clinically demented with neuropathological features as in groups 3 and 4.
Results Table I gives the mean cortical CAT and GAD activities in groups 1-5. Activity of the cholinergic enzyme CAT was significantly decreased only in those cases with Alzheimer-type pathology (groups 4 and 5), whereas activity of the y-aminobutyric acid system enzyme GAD was significantly reduced in all abnormal groups. There were no significant differences between the groups in mean age or mean delay before necropsy (table I) .
Further evidence of a specific involvement of the cholinergic system in Alzheimer-type pathology was provided by analysing the relation between enzyme activities and increasing senile plaque numbers. Figure 1 gives the individual mean CAT activities in the 51 cases and (inset) the mean CAT and GAD activities in cases grouped according to mean plaque count. CAT activities were clearly correlated with increasing plaque formation (r =-082; P < 0-001) but GAD activities were not (r =-0 -21). At lower plaque counts, corresponding to earlier stages of Alzheimer pathology (about 5-10 plaques per field), CAT activity was substantially reduced (to half the activity in the group with no plaques), whereas GAD activity was apparently unaltered. Figure 2 gives changes in other components of the cholinergic system (ACE and MCRB) and BCE in relation to increasing plaque formation. MCRB was apparently unchanged, and although significant correlations were found between mean plaque count and the two cholinesterases, CAT activity still showed the greatest change at lower plaque counts. Figure 3 shows the relation between the cholinergic and y-aminobutyric acid system enzymes (CAT and GAD) and mental test scores in 23 depressed and demented subjects with no ischaemic brain damage (groups 2 and 4). There was clearly a significant correlation between the mental test score and CAT activity (r = 0 81; P < 0 001) but not GAD activity (r=0 16; P>0 05). 
Discussion
Our results suggest a close relation between plaque formation and CAT activity in the cerebral cortex and possibly a specific involvement of the cholinergic system in SDAT. The cholinergicl-4 but not y-aminobutyric acid5 9 system defects, previously reported in SDAT were directly related to the severity of morphological abnormality as measured by the numbers of senile plaques and to the degree of intellectual impairment. Furthermore, our observation that in multi-infarct dementia cortical activities of CAT are apparently normal tend to exclude the possibility that decreased cortical CAT activity in SDAT may be due to non-specific factors such as institutionalisation, terminal illness, and drug treatment. Anticholinergic drugs increase confusion in elderly patients' 1' Premedication with hyoscine induces amnesia"2 13
Hyoscine administered experimentally induces learning deficits and senile cognitive function"4 15
These observations are compatible with a "cholinergic hypothesis" of SDAT in which functional abnormalities are postulated to be associated with defective cholinergic neurotransmission. Table II summarises the biochemical and psychopharmacological evidence in favour of such a hypothesis. In addition to brain biochemical observations, the effects of certain drugs, clinically and experimentally, indicate a possible hypoactivity of cholinergic function in senile dementia and old age. Thus anticholinergic drugs may induce or increase confusion in elderly patients'0 11 and, clinically and experimentally, induce memory deficits and senile intellectual changes in normal adults.' -s' Furthermore, antipsychotic drugs (presumed to antagonise dopaminergic activity) reportedly'6 have fewer extrapyramidal side effects (thought to reflect relative cholinergic hyperactivity) in demented than normal patients, which may indicate diminished cholinergic activity in the demented.
Loss of cortical CAT activity, compared with the other changes in SDAT reported here, may be an early abnormality. Since CAT is principally located in the nerve terminal, ' 7 enzyme loss is compatible with the nerve terminal abnormalities associated with senile plaque formation.'8 Diminished CAT activity could possibly account for the apparent lack of measurable clinical improvement in severely and moderately affected patients given oral choline. 19 20 Although choline enhances cholinergic transmission in normal animal brains,2' it remains to be established as effective in tissue with subnormal CAT activity. And, although the use of cholinergic drugs in diseases of the central nervous system is in its infancy,22 further approaches to countering a cholinergic defect in Alzheimer's dementia include the use of anticholinesterases,23 which might also be combined with CAT substrates such as choline. Furthermore, the possibility that acetylcholine release is defective in SDAT, as it is in the Eaton Lambert syndrome, might be tested by using guanidine, which is clinically useful in the latter condition. 24 The role in SDAT of other neurotransmitter systems that may be amenable to neuropharmacological manipulation is not yet established. In contrast to the cholinergic system, preliminary results on necropsy brain' suggest that the dopaminergic and noradrenergic systems may be spared, and our results do not specifically implicate the y-aminobutyric acid system in Alzheimer-type pathology. Although our findings suggest a close relation between changes in the cholinergic system and SDAT the precise role of this neurotransmitter system in the disease process requires further investigation.
